Patient centric clinical trial services increasing recruitment and retention
Accellacare In-Home Services can be provided in all phases and a wide range of therapeutic areas to:
Accellacare In-Home Services has successfully deployed these services for a range of clinical trials and has a comprehensive network in 60+ countries throughout the world.
Geistek Pharmaceuticals is dedicated to enhancing patient-centricity in clinical trials. With our Accellacare In-Home Services, we bring clinical trial visits directly to patients, offering convenience and flexibility that aligns with their needs.
Our in-home services are available across all phases of clinical trials and cover a wide range of therapeutic areas. By providing clinical trial visits in the comfort of patients’ homes or other convenient locations, we aim to achieve several important objectives.
Firstly, our in-home services contribute to increased patient retention. By reducing the burden on patients, they are less likely to drop out of the trial. Patients appreciate the convenience of receiving individualized attention and support in familiar surroundings, which improves their overall experience and commitment to the trial.
Secondly, our services promote better compliance among patients. With close monitoring and oversight during in-home visits, patients are more likely to adhere to their trial regimen. The personalized approach allows for more effective communication, education, and support, resulting in improved compliance with study protocols.
In addition, our in-home services facilitate accelerated patient enrollment. By providing the option for patients to interact with study staff in the comfort of their homes or at more convenient locations, we expand the reach of clinical trial sites. This enables us to access new patient populations and enhance diversity in trial participation.
Accellacare In-Home Services have been successfully deployed for numerous clinical trials, and our comprehensive network spans over 60 countries worldwide. We have established strong partnerships and a network of experienced healthcare professionals who are dedicated to delivering high-quality care and support to patients participating in clinical trials.
Geistek Pharmaceuticals is committed to patient-centricity and advancing the field of clinical research. By offering Accellacare In-Home Services, we aim to improve patient retention, compliance, enrollment, and diversity in clinical trials. Contact us today to learn more about how our in-home services can benefit your trial and enhance the overall patient experience.
Geistek Pharmaceuticals is committed to a patient-centered approach throughout all stages of drug and device development. With our comprehensive expertise in patient-reported outcomes (PROs), we provide a full-service solution that encompasses the entire treatment lifecycle.
With over four decades of experience in directly engaging with patients, we have developed a deep understanding of their needs and perspectives. Our services cover a wide range of areas, including the development, validation, licensing, translation, cultural validation, and analysis of PROs.
We support pharmaceutical, medical device, and biotechnology companies at every stage of the development process. From endpoint selection and PRO development to the use of PROs in clinical trials and post-approval work, we offer a holistic approach that ensures the integration of patient perspectives into the development and evaluation of healthcare interventions.
Our experts have extensive experience in negotiating with international drug regulatory agencies and healthcare payers to ensure the appropriate use of PROs in clinical trials, drug approval, and reimbursement processes. We have a strong track record in over 200 therapeutic areas, working with more than 200 languages, and maintaining the world’s largest database of PROs and other clinical outcomes assessments (COAs).
Our range of services includes:
Patient-Centered Outcomes: We assist with COA selection, design, and validation; application of COAs in health research; analytics and synthesis of COA data; and the preparation of COA dossiers for regulatory submissions.
COA Databases and Licensing: In collaboration with Mapi Research Trust, we offer targeted literature reviews, COA information search, COA licensing for use in clinical trials, COA scoring guides and manuals, eCOA (electronic COA) solutions, and collaboration with COA developers and copyright holders.
End-to-End eCOA Solutions: We provide instrument verification, COA e-platform interface design, electronic migration, COA vendor management, and patient-centric technology solutions.
Language Services: Our expertise includes translation and linguistic validation of COAs, clinical and medical translation, transcription, voice-overs, and labeling services.
Geistek Pharmaceuticals is dedicated to incorporating patient perspectives and outcomes into the development and evaluation of healthcare interventions. Contact us today to learn more about how our patient-centered outcomes services can support your drug or device development program and enhance patient-centered care.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
